Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$861K Buy
3,810
+207
+6% +$43.9K 0.35% 68
2026
Q2
$778K Sell
3,603
-48
-1% -$9.18K 0.36% 71
2026
Q1
$669K Buy
3,651
+1,136
+45% +$209K 0.38% 75
2025
Q4
$443K Buy
+2,515
New +$411K 0.27% 98

Other funds holding BIIB

XXI Wealth's BIIB Position: Q3 2026 in Review

XXI Wealth increased its Biogen (BIIB) stake by 5.7% in Q3 2026, buying an estimated $43.9K and bringing the position to 3,810 shares worth $861K. The position accounts for 0.35% of the portfolio, ranked #68.

XXI Wealth first reported a position in BIIB in Q4 2025 and has held it in 4 quarters since. 899 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • XXI Wealth held 3,810 shares of Biogen worth $861K as of Q3 2026.
  • XXI Wealth bought 207 Biogen shares in Q3 2026, an estimated $43.9K.
  • Biogen made up 0.35% of XXI Wealth's portfolio in Q3 2026, its #68 holding.
  • XXI Wealth first reported a position in Biogen in Q4 2025 and has held it in 4 quarters since.
  • 899 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on XXI Wealth's 13F filing for Q3 2026, filed 22 Oct 2026.